Georgia Commons

Full bill text

HB1329: HB1329 Controlled substances; Schedule I; provide certain provisions

2025-2026 Regular Session · Enrolled version · Last action May 5, 2026

26 LC 65 0071/AP House Bill 1329 (AS PASSED HOUSE AND SENATE) By: Representatives Stephens of the 164th and Newton of the 127th A BILL TO BE ENTITLED AN ACT To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to1 controlled substances, so as to provide for certain provisions relating to Schedule I controlled2 substances; to provide for certain provisions relating to the definition of dangerous drugs; to3 provide for related matters; to provide for an effective date; to repeal conflicting laws; and4 for other purposes.5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:6 SECTION 1.7 Chapter 13 of Title 16 of the Official Code of Georgia Annotate d, relating to controlled8 substances, is amended in Code Section 16-13-25, relating to Sc hedule I controlled9 substances, by revising subparagraph (E) of paragraph (16) as follows:10 "(E) By substitution at the 5-position or 6-position with a nit ro, alkyl, halide, cyano,11 or acetyl group or primary amine;"12 SECTION 2.13 Said chapter is further amended in Code Section 16-13-71, relat ing to dangerous drug, by14 adding new paragraphs to subsection (b) to read as follows:15 H. B. 1329 - 1 - 26 LC 65 0071/AP "(1.5) Aceclidine;"16 "(12.7) Acoltremon;"17 "(17.2) Aficamten;"18 "(68.45) Atrasentan;"19 "(69.21) Avutometinib;"20 "(91.71) Berahyaluronidase alfa-pmph;"21 "(106.4) Brensocatib;"22 "(196.3) Clesrovimab-cfor;"23 "(240.97) Datopotamab deruxtecan-dlnk;"24 "(243.4) Defactinib;"25 "(244.7) Delgocitinib;"26 "(248.5) Depemokimab-ulaa;"27 "(316.6) Donidalorsen;"28 "(317.15) Dordaviprone;"29 "(318.7) Doxecitine;"30 "(320.5) Doxribtimine;"31 "(331.0513) Elamipretide;"32 "(331.0555) Elinzanetant;"33 "(379.8) Etripamil;"34 "(386.95) Fitusiran;"35 "(411.9) Garadacimab-gxii;"36 "(414.4) Gepotidacin;"37 "(466.7) Imlunestrant;"38 "(513.75) Lerodalcibep-liga;"39 "(523.5) Linvoseltamab-gcpt;"40 "(619.15) Mirdametinib;"41 "(640.105) Nerandomilast;"42 H. B. 1329 - 2 - 26 LC 65 0071/AP "(644.605) Nipocalimab-aahu;"43 "(663.65) Onasemnogene abeparvovec-brve;"44 "(681.65) Paltusotine;"45 "(698.5) Penpulimab-kcqx;"46 "(742.7) Plozasiran;"47 "(768.6) Prademagene zamikeracel;"48 "(832.975) Remibrutinib;"49 "(836.6) Revakinagene taroretcel-lwey;"50 "(842.3) Rilzabrutinib;"51 "(852.055) Sebetralstat;"52 "(855.1) Sepiapterin;"53 "(855.735) Sevabertinib;"54 "(855.83) Sibeprenlimab-szsi;"55 "(927.8) Sunvozertinib;"56 "(929.7) Suzetrigine;"57 "(930.978) Taletrectinib;"58 "(931.565) Telisotuzumab vedotin-tllv;"59 "(974.65) Treosulfan;"60 "(1030.9) Vimseltinib;"61 "(1042.2) Ziftomenib;"62 "(1042.85) Zoliflodacin;"63 "(1042.91) Zongertinib;"64 "(1042.93) Zopapogene imadenovec-drba;"65 SECTION 3.66 Said chapter is further amended in subsection (b) of said Code section by repealing and67 reserving paragraph (324) and by revising paragraphs (60.3), (160.5), and (217.2) as follows:68 H. B. 1329 - 3 - 26 LC 65 0071/AP "(60.3) Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl;"69 "(160.5) Chikungunya vaccine, Live;"70 "(217.2) COVID-19 Vaccine, mRNA;"71 SECTION 4.72 Said chapter is further amended in subsection (c) of said Code section by revising paragraph73 (9.33) as follows:74 "(9.33) Epinephrine —:75 (A) When w h e n used in a device that delivers a metered spray of 0.125 mg. of76 epinephrine or less to provide temporary relief for symptoms of mild, intermittent asthma77 and is a product in finished dosage formulation in its original container that has been78 approved by and labeled in compliance with the U.S. Food and Dr ug Administration79 (FDA); and80 (B) When distributed by a pharmacist as provided by the State Board of Pharmacy, in a81 device that delivers a spray of 2 mg. of epinephrine or less to provide emergency82 treatment of allergic reactions, including anaphylaxis, and is a product in finished dosage83 formulation in its original container that has been approved by and labeled in compliance84 with the U.S. Food and Drug Administration (FDA);"85 SECTION 5.86 This Act shall become effective upon its approval by the Governor or upon its becoming law87 without such approval.88 SECTION 6.89 All laws and parts of laws in conflict with this Act are repealed.90 H. B. 1329 - 4 -
HB1329: Full Text | Georgia Commons